文献速递脊柱关节炎

靶向白介素-6、-12/23和-17通路的生物制剂治疗外周型银屑病关节炎的疗效与安全性:一项网状Meta分析

Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

该网状Meta分析纳入6项随机对照试验、共2411例活动性银屑病关节炎患者和11种治疗,评估靶向IL-6、IL-12/23和IL-17通路生物制剂的疗效、安全性与耐受性。两两Meta分析显示司库奇尤单抗、乌司奴单抗和依奇珠单抗在达到ACR20和ACR50缓解方面优于安慰剂;网状Meta分析显示司库奇尤单抗(300 mg每月)在达到ACR20和ACR50方面疗效最高。作者认为司库奇尤单抗可能是短期治疗外周型银屑病关节炎最安全且最有效的生物制剂。

要点

  • 两两Meta分析显示司库奇尤单抗、乌司奴单抗和依奇珠单抗在ACR20和ACR50缓解上优于安慰剂。
  • 依奇珠单抗的不良事件发生率高于安慰剂,乌司奴单抗因不良事件停药的可能性低于安慰剂。
  • 网状Meta分析显示司库奇尤单抗(300 mg每月)在ACR20和ACR50缓解上疗效最高。

核心结论

  • 作者认为,在靶向IL-6、IL-12/23和IL-17通路的所有新型生物制剂中,司库奇尤单抗可能是短期治疗外周型银屑病关节炎最安全且最有效的药物。
  • 综合考虑总体风险-获益特征,司库奇尤单抗(150 mg每月)可能为外周型银屑病关节炎患者提供最佳平衡。

研究设计与样本

  • 通过全面系统文献综述识别评估IL-6、IL-12/23和IL-17抑制剂疗效、安全性和耐受性的随机对照试验。
  • 共纳入6项试验,包含2411例参与者和11种治疗。
  • 采用随机效应模型进行两两Meta分析和贝叶斯网状Meta分析,估计达到ACR20和ACR50的合并比值比(OR)及95%可信区间。

主要发现

  • 两两Meta分析显示,司库奇尤单抗、乌司奴单抗和依奇珠单抗在达到ACR20和ACR50缓解方面疗效优于安慰剂。
  • 依奇珠单抗的不良事件发生率高于安慰剂。
  • 乌司奴单抗的耐受性高于安慰剂(因不良事件停药的可能性更低)。
  • 网状Meta分析显示,司库奇尤单抗(300 mg每月)在达到ACR20和ACR50方面疗效最高。
  • 网状Meta分析显示,克拉扎奇单抗(200 mg每月)、乌司奴单抗(45 mg每12周)和司库奇尤单抗(150 mg每月)分别发生不良事件、严重不良事件和不可耐受性的概率最低。

关键数值与推荐

  • 纳入6项随机对照试验,共2411例参与者和11种治疗。
  • 疗效指标为达到ACR20和ACR50缓解的合并OR及95%可信区间。
  • 司库奇尤单抗(300 mg每月)在ACR20和ACR50缓解上疗效最高。
  • 克拉扎奇单抗(200 mg每月)发生不良事件的概率最低,乌司奴单抗(45 mg每12周)发生严重不良事件的概率最低,司库奇尤单抗(150 mg每月)发生不可耐受性的概率最低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the comparative efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors for patients with active PsA. METHODS: Randomized controlled trials evaluating the efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors were identified by a comprehensive systematic literature review. Pairwise meta-analyses and Bayesian network meta-analyses using the random effects model were performed to estimate pooled odds ratios (ORs) and 95% credible intervals of attaining a 20% or 50% improvement in ACR criteria (ACR20 and ACR50, respectively) across trials. RESULTS: Six trials were identified that included 2411 participants and 11 treatments. Pairwise meta-analysis showed that secukinumab, ustekinumab and ixekizumab demonstrated superior efficacy over placebo in achieving an ACR20 and ACR50 response. However, ixekizumab has a higher incidence of adverse events (AEs) than placebo. In contrast, ustekinumab has a higher tolerability (less likely to be discontinued due to AEs) than placebo. Network meta-analysis showed that secukinumab (300 mg monthly) had the highest efficacy in achieving ACR20 and ACR50, whereas clazakizumab (200 mg monthly), ustekinumab (45 mg 12 weekly) and secukinumab (150 mg monthly) had the lowest probability of having AEs, serious AEs and intolerability, respectively. Considering the overall risk-benefit profile, secukinumab (150 mg monthly) may offer an optimal balance for peripheral PsA patients. CONCLUSION: Secukinumab may be the safest and most efficacious short-term treatment for peripheral PsA among all the new biologics targeting IL-6, IL-12/23 and IL-17 pathways.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wu D, Yue J, Tam LS, et al. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford). 2018. PMID: 29244162. doi:10.1093/rheumatology/kex452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。